High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Severe-grade Checkpoint Inhibitor Pneumonitis in Lung Cancer

High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Severe-grade Checkpoint Inhibitor Pneumonitis in Lung Cancer - High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Severe-grade Checkpoint Inhibitor Pneumonitis in Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037184

Enrollment

Registered

2019-06-26

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This retrospective cohort study include patients with stage IV or unresectable stage III or postoperative recurrent NSCLC treated with ICI between January 2016 and January 2019 in our institution.

Exclusion criteria

Exclusion criteria: Patients, or family refuse to participate in this study.

Design outcomes

Primary

Measure	Time frame
Mortality of Immune Checkpoint Inhibitors in Severe-grade Checkpoint Inhibitor Pneumonitis	—

Secondary

Measure	Time frame
Treatment Efficacy of Immune Checkpoint Inhibitors in Severe-grade Checkpoint Inhibitor Pneumonitis	—

Countries

Japan

Contacts

Public ContactMari Tone

Japanese Red Cross Medical Center Department of Respiratory Medicine

m.tone.0829@gmail.com03-3400-1311

Outcome results